Breast Cancer

Key clinical point: High cardiorespiratory fitness (CRF) may prevent the development of breast cancer (BC) in postmenopausal women.

Major finding: Compared with women with low-to-moderate estimated CRF, those with high eCRF had 24% lower odds of developing BC (adjusted subdistribution hazard ratio 0.76; 95% CI 0.60-0.97).

Study details: This study used the UK Biobank data to evaluate 17,840 post-menopausal women who were free of cancer and were followed for 11 years, of which 529 women developed BC.

Disclosures: This project was funded in part by the Canadian Institutes of Health Research and discretionary funds held by JD Brooks. The authors declared no conflicts of interest.

Source: Christensen RAG et al. Association between estimated cardiorespiratory fitness and breast cancer: A prospective cohort study. Br J Sports Med. 2023 (Jun 19). Doi: 10.1136/bjsports-2021-104870

Key clinical point: High cardiorespiratory fitness (CRF) may prevent the development of breast cancer (BC) in postmenopausal women.

Major finding: Compared with women with low-to-moderate estimated CRF, those with high eCRF had 24% lower odds of developing BC (adjusted subdistribution hazard ratio 0.76; 95% CI 0.60-0.97).

Study details: This study used the UK Biobank data to evaluate 17,840 post-menopausal women who were free of cancer and were followed for 11 years, of which 529 women developed BC.

Disclosures: This project was funded in part by the Canadian Institutes of Health Research and discretionary funds held by JD Brooks. The authors declared no conflicts of interest.

Source: Christensen RAG et al. Association between estimated cardiorespiratory fitness and breast cancer: A prospective cohort study. Br J Sports Med. 2023 (Jun 19). Doi: 10.1136/bjsports-2021-104870

Key clinical point: High cardiorespiratory fitness (CRF) may prevent the development of breast cancer (BC) in postmenopausal women.

Major finding: Compared with women with low-to-moderate estimated CRF, those with high eCRF had 24% lower odds of developing BC (adjusted subdistribution hazard ratio 0.76; 95% CI 0.60-0.97).

Study details: This study used the UK Biobank data to evaluate 17,840 post-menopausal women who were free of cancer and were followed for 11 years, of which 529 women developed BC.

Disclosures: This project was funded in part by the Canadian Institutes of Health Research and discretionary funds held by JD Brooks. The authors declared no conflicts of interest.

Source: Christensen RAG et al. Association between estimated cardiorespiratory fitness and breast cancer: A prospective cohort study. Br J Sports Med. 2023 (Jun 19). Doi: 10.1136/bjsports-2021-104870

Key clinical point: Breast-conserving surgery (BCS) led to similar overall survival (OS) and better disease-specific survival (DSS) outcomes compared with mastectomy in patients with stage I/II adenoid cystic carcinoma of the breast (BACC).

Major finding: The 10-year OS rates were comparable between the BCS and mastectomy groups (P = .968), whereas DSS was significantly improved in patients who underwent BCS vs mastectomy (95% vs 89%; P = .002).

Study details: Findings are from an analysis of the Surveillance, Epidemiology, and End Results Program (SEER) including 583 patients with stage I/II BACC, of whom 386 patients underwent BCS and 197 patients underwent mastectomy.

Disclosures: This study was supported by various grants from the Science and Technology Department of Henan Province, China. The authors declared no conflicts of interest.

Source: Huang T et al. Optimal surgical procedure for treating early-stage adenoid cystic carcinoma of the breast. Sci Rep. 2023;13:10222 (Jun 23). Doi: 10.1038/s41598-023-36644-w

Key clinical point: Breast-conserving surgery (BCS) led to similar overall survival (OS) and better disease-specific survival (DSS) outcomes compared with mastectomy in patients with stage I/II adenoid cystic carcinoma of the breast (BACC).

Major finding: The 10-year OS rates were comparable between the BCS and mastectomy groups (P = .968), whereas DSS was significantly improved in patients who underwent BCS vs mastectomy (95% vs 89%; P = .002).

Study details: Findings are from an analysis of the Surveillance, Epidemiology, and End Results Program (SEER) including 583 patients with stage I/II BACC, of whom 386 patients underwent BCS and 197 patients underwent mastectomy.

Disclosures: This study was supported by various grants from the Science and Technology Department of Henan Province, China. The authors declared no conflicts of interest.

Source: Huang T et al. Optimal surgical procedure for treating early-stage adenoid cystic carcinoma of the breast. Sci Rep. 2023;13:10222 (Jun 23). Doi: 10.1038/s41598-023-36644-w

Key clinical point: Breast-conserving surgery (BCS) led to similar overall survival (OS) and better disease-specific survival (DSS) outcomes compared with mastectomy in patients with stage I/II adenoid cystic carcinoma of the breast (BACC).

Major finding: The 10-year OS rates were comparable between the BCS and mastectomy groups (P = .968), whereas DSS was significantly improved in patients who underwent BCS vs mastectomy (95% vs 89%; P = .002).

Study details: Findings are from an analysis of the Surveillance, Epidemiology, and End Results Program (SEER) including 583 patients with stage I/II BACC, of whom 386 patients underwent BCS and 197 patients underwent mastectomy.

Disclosures: This study was supported by various grants from the Science and Technology Department of Henan Province, China. The authors declared no conflicts of interest.

Source: Huang T et al. Optimal surgical procedure for treating early-stage adenoid cystic carcinoma of the breast. Sci Rep. 2023;13:10222 (Jun 23). Doi: 10.1038/s41598-023-36644-w

Key clinical point: Adherence and persistence to adjuvant hormone therapy was associated with improved survival outcomes in older women with hormone receptor-positive (HR+) breast cancer (BC).

Major finding: The risk for all-cause mortality reduced by 25% in patients with vs without cumulative adherence to hormone therapy (hazard ratio [HR] 0.75; P < .001) and decreased by 11% for every 1-year increase in persistence (HR 0.89; P < .001). Each 1-year increase in persistence to hormone therapy also significantly improved breast cancer-specific mortality (HR 0.63; P < .001).

Study details: Findings are from a retrospective analysis of the Surveillance, Epidemiology, and End Results (SEER) data linked with US Medicare claims that included 25,796 older women with HR+ BC who were ≥66 years old and received adjuvant hormone therapy.

Disclosures: This study was partly supported by a grant from the Lilly Endowment, Inc. The authors declared no conflicts of interest.

Source: Zheng D and Thomas J 3rd. Survival benefits associated with being adherent and having longer persistence to adjuvant hormone therapy across up to five years among U.S. Medicare population with breast cancer. Breast Cancer Res Treat. 2023;201:89-104 (Jun 16). Doi: 10.1007/s10549-023-06992-2

Key clinical point: Adherence and persistence to adjuvant hormone therapy was associated with improved survival outcomes in older women with hormone receptor-positive (HR+) breast cancer (BC).

Major finding: The risk for all-cause mortality reduced by 25% in patients with vs without cumulative adherence to hormone therapy (hazard ratio [HR] 0.75; P < .001) and decreased by 11% for every 1-year increase in persistence (HR 0.89; P < .001). Each 1-year increase in persistence to hormone therapy also significantly improved breast cancer-specific mortality (HR 0.63; P < .001).

Study details: Findings are from a retrospective analysis of the Surveillance, Epidemiology, and End Results (SEER) data linked with US Medicare claims that included 25,796 older women with HR+ BC who were ≥66 years old and received adjuvant hormone therapy.

Disclosures: This study was partly supported by a grant from the Lilly Endowment, Inc. The authors declared no conflicts of interest.

Source: Zheng D and Thomas J 3rd. Survival benefits associated with being adherent and having longer persistence to adjuvant hormone therapy across up to five years among U.S. Medicare population with breast cancer. Breast Cancer Res Treat. 2023;201:89-104 (Jun 16). Doi: 10.1007/s10549-023-06992-2

Key clinical point: Adherence and persistence to adjuvant hormone therapy was associated with improved survival outcomes in older women with hormone receptor-positive (HR+) breast cancer (BC).

Major finding: The risk for all-cause mortality reduced by 25% in patients with vs without cumulative adherence to hormone therapy (hazard ratio [HR] 0.75; P < .001) and decreased by 11% for every 1-year increase in persistence (HR 0.89; P < .001). Each 1-year increase in persistence to hormone therapy also significantly improved breast cancer-specific mortality (HR 0.63; P < .001).

Study details: Findings are from a retrospective analysis of the Surveillance, Epidemiology, and End Results (SEER) data linked with US Medicare claims that included 25,796 older women with HR+ BC who were ≥66 years old and received adjuvant hormone therapy.

Disclosures: This study was partly supported by a grant from the Lilly Endowment, Inc. The authors declared no conflicts of interest.

Source: Zheng D and Thomas J 3rd. Survival benefits associated with being adherent and having longer persistence to adjuvant hormone therapy across up to five years among U.S. Medicare population with breast cancer. Breast Cancer Res Treat. 2023;201:89-104 (Jun 16). Doi: 10.1007/s10549-023-06992-2

Key clinical point: Although patients with early breast cancer (BC) can undergo immediate breast reconstruction (IBR) after mastectomy, those with invasive BC should be made aware of the possibility of local recurrence (LR) if they have undergone skin- or nipple-sparing mastectomy (SSM/NSM), have not received radiotherapy, or had lymphovascular invasion or cancer at the surgical margin.

Major finding: The rate of 7-year LR was generally low (3.6%) but was higher in invasive vs non-invasive BC (4.3% vs 2.1%; P < .001). SSM/NSM (P < .001), lymphovascular invasion (P = .005), cancer at the surgical margin (P < .001), and no radiotherapy (P = .003) were associated with worse LR rates in invasive BC.

Study details: This retrospective, observational study included 4153 patients with early BC who underwent mastectomy with IBR, of which 2851 and 1272 patients had invasive and non-invasive BC, respectively.

Disclosures: This study was supported by a grant from the scientific committee of the Japanese Breast Cancer Society. The authors declared no conflicts of interest.

Source: Ogiya A et al, on behalf of Collaborative Study Group of Scientific Research of the Japanese Breast Cancer Society. Long-term outcomes of breast cancer patients with local recurrence after mastectomy undergoing immediate breast reconstruction: A retrospective multi-institutional study of 4153 cases. Ann Surg Oncol. 2023 (Jul 5). Doi: 10.1245/s10434-023-13832-6

Key clinical point: Although patients with early breast cancer (BC) can undergo immediate breast reconstruction (IBR) after mastectomy, those with invasive BC should be made aware of the possibility of local recurrence (LR) if they have undergone skin- or nipple-sparing mastectomy (SSM/NSM), have not received radiotherapy, or had lymphovascular invasion or cancer at the surgical margin.

Major finding: The rate of 7-year LR was generally low (3.6%) but was higher in invasive vs non-invasive BC (4.3% vs 2.1%; P < .001). SSM/NSM (P < .001), lymphovascular invasion (P = .005), cancer at the surgical margin (P < .001), and no radiotherapy (P = .003) were associated with worse LR rates in invasive BC.

Study details: This retrospective, observational study included 4153 patients with early BC who underwent mastectomy with IBR, of which 2851 and 1272 patients had invasive and non-invasive BC, respectively.

Disclosures: This study was supported by a grant from the scientific committee of the Japanese Breast Cancer Society. The authors declared no conflicts of interest.

Source: Ogiya A et al, on behalf of Collaborative Study Group of Scientific Research of the Japanese Breast Cancer Society. Long-term outcomes of breast cancer patients with local recurrence after mastectomy undergoing immediate breast reconstruction: A retrospective multi-institutional study of 4153 cases. Ann Surg Oncol. 2023 (Jul 5). Doi: 10.1245/s10434-023-13832-6

Key clinical point: Although patients with early breast cancer (BC) can undergo immediate breast reconstruction (IBR) after mastectomy, those with invasive BC should be made aware of the possibility of local recurrence (LR) if they have undergone skin- or nipple-sparing mastectomy (SSM/NSM), have not received radiotherapy, or had lymphovascular invasion or cancer at the surgical margin.

Major finding: The rate of 7-year LR was generally low (3.6%) but was higher in invasive vs non-invasive BC (4.3% vs 2.1%; P < .001). SSM/NSM (P < .001), lymphovascular invasion (P = .005), cancer at the surgical margin (P < .001), and no radiotherapy (P = .003) were associated with worse LR rates in invasive BC.

Study details: This retrospective, observational study included 4153 patients with early BC who underwent mastectomy with IBR, of which 2851 and 1272 patients had invasive and non-invasive BC, respectively.

Disclosures: This study was supported by a grant from the scientific committee of the Japanese Breast Cancer Society. The authors declared no conflicts of interest.

Source: Ogiya A et al, on behalf of Collaborative Study Group of Scientific Research of the Japanese Breast Cancer Society. Long-term outcomes of breast cancer patients with local recurrence after mastectomy undergoing immediate breast reconstruction: A retrospective multi-institutional study of 4153 cases. Ann Surg Oncol. 2023 (Jul 5). Doi: 10.1245/s10434-023-13832-6

Key clinical point: Invasive lobular carcinoma (ILC), the most common special histological type of breast cancer (BC), had poorer survival outcomes than invasive ductal carcinoma (IDC) and no-lobular special type BC.

Major finding: Patients with ILC vs no-lobular special type BC and IDC had the shortest duration of both disease-free survival (197.2 vs 216.7 and 226.5 months, respectively) and overall survival (209.8 vs 227.9 and 233.2 months, respectively), and ILC vs IDC was associated with significantly worse overall survival (hazard ratio 1.45; P = .045).

Study details: Findings are from a retrospective study including 2157 patients with invasive carcinoma of the breast who were categorized into IDC (n = 1814), ILC (n = 193), and no-lobular special type BC (n = 150).

Disclosures: This study did not receive any specific funding. The authors declared no conflicts of interest.

Source: Cosar R et al. Classifying invasive lobular carcinoma as special type breast cancer may be reducing its treatment success: A comparison of survival among invasive lobular carcinoma, invasive ductal carcinoma, and no-lobular special type breast cancer. PLoS One. 2023;18(7):e0283445 (Jul 10). Doi: 10.1371/journal.pone.0283445

Key clinical point: Invasive lobular carcinoma (ILC), the most common special histological type of breast cancer (BC), had poorer survival outcomes than invasive ductal carcinoma (IDC) and no-lobular special type BC.

Major finding: Patients with ILC vs no-lobular special type BC and IDC had the shortest duration of both disease-free survival (197.2 vs 216.7 and 226.5 months, respectively) and overall survival (209.8 vs 227.9 and 233.2 months, respectively), and ILC vs IDC was associated with significantly worse overall survival (hazard ratio 1.45; P = .045).

Study details: Findings are from a retrospective study including 2157 patients with invasive carcinoma of the breast who were categorized into IDC (n = 1814), ILC (n = 193), and no-lobular special type BC (n = 150).

Disclosures: This study did not receive any specific funding. The authors declared no conflicts of interest.

Source: Cosar R et al. Classifying invasive lobular carcinoma as special type breast cancer may be reducing its treatment success: A comparison of survival among invasive lobular carcinoma, invasive ductal carcinoma, and no-lobular special type breast cancer. PLoS One. 2023;18(7):e0283445 (Jul 10). Doi: 10.1371/journal.pone.0283445

Key clinical point: Invasive lobular carcinoma (ILC), the most common special histological type of breast cancer (BC), had poorer survival outcomes than invasive ductal carcinoma (IDC) and no-lobular special type BC.

Major finding: Patients with ILC vs no-lobular special type BC and IDC had the shortest duration of both disease-free survival (197.2 vs 216.7 and 226.5 months, respectively) and overall survival (209.8 vs 227.9 and 233.2 months, respectively), and ILC vs IDC was associated with significantly worse overall survival (hazard ratio 1.45; P = .045).

Study details: Findings are from a retrospective study including 2157 patients with invasive carcinoma of the breast who were categorized into IDC (n = 1814), ILC (n = 193), and no-lobular special type BC (n = 150).

Disclosures: This study did not receive any specific funding. The authors declared no conflicts of interest.

Source: Cosar R et al. Classifying invasive lobular carcinoma as special type breast cancer may be reducing its treatment success: A comparison of survival among invasive lobular carcinoma, invasive ductal carcinoma, and no-lobular special type breast cancer. PLoS One. 2023;18(7):e0283445 (Jul 10). Doi: 10.1371/journal.pone.0283445

Key clinical point: A higher body mass index (BMI) was not linked directly to survival outcomes but was linked to worse prognostic clinicopathologic variables in estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2−) invasive lobular carcinoma (ILC) of the breast.

Major finding: Although BMI was not directly associated with disease-free survival and overall survival outcomes (both P = .08), a higher BMI was associated with larger tumor size (≥2 cm; P < .001), higher tumor grade (grade 3; P = .014), nodal involvement (P < .001), and multifocal BC (P = .01), which indicated significantly worsened prognosis.

Study details: This multicenter, retrospective study included 2490 patients with ER+/HER2− ILC of the breast, of which 1410, 712, and 368 patients were lean, overweight, and obese, respectively.

Disclosures: This study was funded by the Luxembourg Cancer Foundation and other sources. The authors declared no conflicts of interest.

Source: Baelen KV, Nguyen H-L, et al. Association of body mass index with clinicopathological features and survival in patients with primary invasive lobular breast cancer. Eur J Cancer. 2023;112988 (Jul 12). Doi: 10.1016/j.ejca.2023.112988

Key clinical point: A higher body mass index (BMI) was not linked directly to survival outcomes but was linked to worse prognostic clinicopathologic variables in estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2−) invasive lobular carcinoma (ILC) of the breast.

Major finding: Although BMI was not directly associated with disease-free survival and overall survival outcomes (both P = .08), a higher BMI was associated with larger tumor size (≥2 cm; P < .001), higher tumor grade (grade 3; P = .014), nodal involvement (P < .001), and multifocal BC (P = .01), which indicated significantly worsened prognosis.

Study details: This multicenter, retrospective study included 2490 patients with ER+/HER2− ILC of the breast, of which 1410, 712, and 368 patients were lean, overweight, and obese, respectively.

Disclosures: This study was funded by the Luxembourg Cancer Foundation and other sources. The authors declared no conflicts of interest.

Source: Baelen KV, Nguyen H-L, et al. Association of body mass index with clinicopathological features and survival in patients with primary invasive lobular breast cancer. Eur J Cancer. 2023;112988 (Jul 12). Doi: 10.1016/j.ejca.2023.112988

Key clinical point: A higher body mass index (BMI) was not linked directly to survival outcomes but was linked to worse prognostic clinicopathologic variables in estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2−) invasive lobular carcinoma (ILC) of the breast.

Major finding: Although BMI was not directly associated with disease-free survival and overall survival outcomes (both P = .08), a higher BMI was associated with larger tumor size (≥2 cm; P < .001), higher tumor grade (grade 3; P = .014), nodal involvement (P < .001), and multifocal BC (P = .01), which indicated significantly worsened prognosis.

Study details: This multicenter, retrospective study included 2490 patients with ER+/HER2− ILC of the breast, of which 1410, 712, and 368 patients were lean, overweight, and obese, respectively.

Disclosures: This study was funded by the Luxembourg Cancer Foundation and other sources. The authors declared no conflicts of interest.

Source: Baelen KV, Nguyen H-L, et al. Association of body mass index with clinicopathological features and survival in patients with primary invasive lobular breast cancer. Eur J Cancer. 2023;112988 (Jul 12). Doi: 10.1016/j.ejca.2023.112988

Key clinical point: Adjuvant radiotherapy treatment interruption for a greater number of days was associated with worsened survival outcomes in patients with nonmetastatic triple-negative breast cancer (TNBC).

Major finding: As little as 2-5 days of treatment interruption worsened the overall survival outcomes in patients with TNBC compared with 0-1 day (hazard ratio [HR] 1.069; 95% CI 1.002-1.140), with the mortality risk increasing further in case of 6-10 days (HR 1.236; 95% CI 1.137-1.345) and 11-15 days (HR 1.259; 95% CI 1.112-1.415) of treatment interruption.

Study details: This study analyzed the data of 35,845 patients with nonmetastatic TNBC from the US National Cancer Database who had received external beam radiation therapy and had an overall survival of at least 12 months.

Disclosures: This study was partly funded by the US National Institutes of Health/National Cancer Institute (NIH/NCI) Cancer Center support grant. The authors declared no conflicts of interest.

Source: Chow R et al. Effect of treatment interruptions on overall survival in patients with triple negative breast cancer. J Natl Cancer Inst. 2023 (Jul 3). Doi: 10.1093/jnci/djad127

Key clinical point: Adjuvant radiotherapy treatment interruption for a greater number of days was associated with worsened survival outcomes in patients with nonmetastatic triple-negative breast cancer (TNBC).

Major finding: As little as 2-5 days of treatment interruption worsened the overall survival outcomes in patients with TNBC compared with 0-1 day (hazard ratio [HR] 1.069; 95% CI 1.002-1.140), with the mortality risk increasing further in case of 6-10 days (HR 1.236; 95% CI 1.137-1.345) and 11-15 days (HR 1.259; 95% CI 1.112-1.415) of treatment interruption.

Study details: This study analyzed the data of 35,845 patients with nonmetastatic TNBC from the US National Cancer Database who had received external beam radiation therapy and had an overall survival of at least 12 months.

Disclosures: This study was partly funded by the US National Institutes of Health/National Cancer Institute (NIH/NCI) Cancer Center support grant. The authors declared no conflicts of interest.

Source: Chow R et al. Effect of treatment interruptions on overall survival in patients with triple negative breast cancer. J Natl Cancer Inst. 2023 (Jul 3). Doi: 10.1093/jnci/djad127

Key clinical point: Adjuvant radiotherapy treatment interruption for a greater number of days was associated with worsened survival outcomes in patients with nonmetastatic triple-negative breast cancer (TNBC).

Major finding: As little as 2-5 days of treatment interruption worsened the overall survival outcomes in patients with TNBC compared with 0-1 day (hazard ratio [HR] 1.069; 95% CI 1.002-1.140), with the mortality risk increasing further in case of 6-10 days (HR 1.236; 95% CI 1.137-1.345) and 11-15 days (HR 1.259; 95% CI 1.112-1.415) of treatment interruption.

Study details: This study analyzed the data of 35,845 patients with nonmetastatic TNBC from the US National Cancer Database who had received external beam radiation therapy and had an overall survival of at least 12 months.

Disclosures: This study was partly funded by the US National Institutes of Health/National Cancer Institute (NIH/NCI) Cancer Center support grant. The authors declared no conflicts of interest.

Source: Chow R et al. Effect of treatment interruptions on overall survival in patients with triple negative breast cancer. J Natl Cancer Inst. 2023 (Jul 3). Doi: 10.1093/jnci/djad127

Key clinical point: Female patients with meningioma have approximately 10-fold higher odds of developing breast cancer (BC) and should be screened more often for BC.

Major finding: Compared with the general population, the prevalence of BC was considerably higher in female patients with meningioma (odds ratio 9.87; 95% CI 7.31-13.32).

Study details: Findings are from a meta-analysis of 18 studies including patients diagnosed with intracranial or spinal meningioma or BC or both.

Disclosures: This study did not report the source of funding. The authors declared no conflicts of interest.

Source: Degeneffe A et al. The association between meningioma and breast cancer: A systematic review and meta-analysis. JAMA Netw Open. 2023;6(6):e2318620 (Jun 16). Doi: 10.1001/jamanetworkopen.2023.18620

Key clinical point: Female patients with meningioma have approximately 10-fold higher odds of developing breast cancer (BC) and should be screened more often for BC.

Major finding: Compared with the general population, the prevalence of BC was considerably higher in female patients with meningioma (odds ratio 9.87; 95% CI 7.31-13.32).

Study details: Findings are from a meta-analysis of 18 studies including patients diagnosed with intracranial or spinal meningioma or BC or both.

Disclosures: This study did not report the source of funding. The authors declared no conflicts of interest.

Source: Degeneffe A et al. The association between meningioma and breast cancer: A systematic review and meta-analysis. JAMA Netw Open. 2023;6(6):e2318620 (Jun 16). Doi: 10.1001/jamanetworkopen.2023.18620

Key clinical point: Female patients with meningioma have approximately 10-fold higher odds of developing breast cancer (BC) and should be screened more often for BC.

Major finding: Compared with the general population, the prevalence of BC was considerably higher in female patients with meningioma (odds ratio 9.87; 95% CI 7.31-13.32).

Study details: Findings are from a meta-analysis of 18 studies including patients diagnosed with intracranial or spinal meningioma or BC or both.

Disclosures: This study did not report the source of funding. The authors declared no conflicts of interest.

Source: Degeneffe A et al. The association between meningioma and breast cancer: A systematic review and meta-analysis. JAMA Netw Open. 2023;6(6):e2318620 (Jun 16). Doi: 10.1001/jamanetworkopen.2023.18620

Key clinical point: Adherence to a Mediterranean diet before being diagnosed with breast cancer (BC) may improve survival outcomes, particularly in postmenopausal women.

Major finding: A low vs medium adherence to Mediterranean diet was associated with a 13% higher risk for all-cause mortality (hazard ratio [HR] 1.13;  95% CI 1.01-1.26). The risk for overall mortality reduced by 8% (HR 0.92;  95% CI 0.87-0.97) for every 3-unit increase in the adapted relative Mediterranean diet score, with the association sustaining in case of postmenopausal women only.

Study details: Findings are from an analysis including 13,270 women with incident BC from a prospective, multicenter European cohort of 318,686 women.

Disclosures: This study was funded by the AECC Scientific Foundation. The authors declared no conflicts of interest.

Source: Castro-Espin C et al. Association of Mediterranean diet with survival after breast cancer diagnosis in women from nine European countries: Results from the EPIC cohort study. BMC Med. 2023;21:225 (Jun 26). Doi: 10.1186/s12916-023-02934-3

Key clinical point: Adherence to a Mediterranean diet before being diagnosed with breast cancer (BC) may improve survival outcomes, particularly in postmenopausal women.

Major finding: A low vs medium adherence to Mediterranean diet was associated with a 13% higher risk for all-cause mortality (hazard ratio [HR] 1.13;  95% CI 1.01-1.26). The risk for overall mortality reduced by 8% (HR 0.92;  95% CI 0.87-0.97) for every 3-unit increase in the adapted relative Mediterranean diet score, with the association sustaining in case of postmenopausal women only.

Study details: Findings are from an analysis including 13,270 women with incident BC from a prospective, multicenter European cohort of 318,686 women.

Disclosures: This study was funded by the AECC Scientific Foundation. The authors declared no conflicts of interest.

Source: Castro-Espin C et al. Association of Mediterranean diet with survival after breast cancer diagnosis in women from nine European countries: Results from the EPIC cohort study. BMC Med. 2023;21:225 (Jun 26). Doi: 10.1186/s12916-023-02934-3

Key clinical point: Adherence to a Mediterranean diet before being diagnosed with breast cancer (BC) may improve survival outcomes, particularly in postmenopausal women.

Major finding: A low vs medium adherence to Mediterranean diet was associated with a 13% higher risk for all-cause mortality (hazard ratio [HR] 1.13;  95% CI 1.01-1.26). The risk for overall mortality reduced by 8% (HR 0.92;  95% CI 0.87-0.97) for every 3-unit increase in the adapted relative Mediterranean diet score, with the association sustaining in case of postmenopausal women only.

Study details: Findings are from an analysis including 13,270 women with incident BC from a prospective, multicenter European cohort of 318,686 women.

Disclosures: This study was funded by the AECC Scientific Foundation. The authors declared no conflicts of interest.

Source: Castro-Espin C et al. Association of Mediterranean diet with survival after breast cancer diagnosis in women from nine European countries: Results from the EPIC cohort study. BMC Med. 2023;21:225 (Jun 26). Doi: 10.1186/s12916-023-02934-3

Key clinical point: Findings from this real-world study supported the previous evidence for improved clinical outcomes on adding pertuzumab to trastuzumab plus neoadjuvant chemotherapy (TCT) in patients with human epidermal growth factor receptor 2-positive (HER2+) early-stage breast cancer (BC).

Major finding: The pathological complete response (odds ratio 1.74; P = .032) and 5-year event-free survival (hazard ratio, 2.22; P = .041) rates were significantly worsened in patients receiving TCT vs pertuzumab+TCT. The incidence of serious adverse events did not differ significantly between both groups.

Study details: Findings are from a retrospective, observational study including 271 patients with HER2+ stage II-III BC who received TCT with (n = 137) or without pertuzumab (n = 134).

Disclosures: This study did not declare the source of funding. The authors declared no conflicts of interest.

Source: Fabbri A et al. Pathologic response and survival after neoadjuvant chemotherapy with or without pertuzumab in patients with HER2-positive breast cancer: The Neopearl nationwide collaborative study. Front Oncol. 2023;13:1177681 (Jun 27). Doi: 10.3389/fonc.2023.1177681

Key clinical point: Findings from this real-world study supported the previous evidence for improved clinical outcomes on adding pertuzumab to trastuzumab plus neoadjuvant chemotherapy (TCT) in patients with human epidermal growth factor receptor 2-positive (HER2+) early-stage breast cancer (BC).

Major finding: The pathological complete response (odds ratio 1.74; P = .032) and 5-year event-free survival (hazard ratio, 2.22; P = .041) rates were significantly worsened in patients receiving TCT vs pertuzumab+TCT. The incidence of serious adverse events did not differ significantly between both groups.

Study details: Findings are from a retrospective, observational study including 271 patients with HER2+ stage II-III BC who received TCT with (n = 137) or without pertuzumab (n = 134).

Disclosures: This study did not declare the source of funding. The authors declared no conflicts of interest.

Source: Fabbri A et al. Pathologic response and survival after neoadjuvant chemotherapy with or without pertuzumab in patients with HER2-positive breast cancer: The Neopearl nationwide collaborative study. Front Oncol. 2023;13:1177681 (Jun 27). Doi: 10.3389/fonc.2023.1177681

Key clinical point: Findings from this real-world study supported the previous evidence for improved clinical outcomes on adding pertuzumab to trastuzumab plus neoadjuvant chemotherapy (TCT) in patients with human epidermal growth factor receptor 2-positive (HER2+) early-stage breast cancer (BC).

Major finding: The pathological complete response (odds ratio 1.74; P = .032) and 5-year event-free survival (hazard ratio, 2.22; P = .041) rates were significantly worsened in patients receiving TCT vs pertuzumab+TCT. The incidence of serious adverse events did not differ significantly between both groups.

Study details: Findings are from a retrospective, observational study including 271 patients with HER2+ stage II-III BC who received TCT with (n = 137) or without pertuzumab (n = 134).

Disclosures: This study did not declare the source of funding. The authors declared no conflicts of interest.

Source: Fabbri A et al. Pathologic response and survival after neoadjuvant chemotherapy with or without pertuzumab in patients with HER2-positive breast cancer: The Neopearl nationwide collaborative study. Front Oncol. 2023;13:1177681 (Jun 27). Doi: 10.3389/fonc.2023.1177681